Navigation Links
Une plainte contre une organisation du Prix Nobel pour diffamation et concurrence deloyale est déposée pour la première fois
Date:12/7/2012

LOS ANGELES, 7 décembre 2012 /PRNewswire/ - Le Dr Rongxiang Xu, fondateur de la « médecine régénérative du corps humain » et biologiste et scientifique médical de renom, a déposé aujourd'hui une plainte contre l'Assemblée des Nobel de l'Institut Karolinska, un organisme suédois, connu sous le nom de Nobelforsamlingen. L'Assemblée des Nobel de l'Institut Karolinska est un organisme qui décerne le Prix Nobel de physiologie et de médicine. La plainte, pour diffamation et concurrence déloyale, a été déposée auprès de la Cour Supérieure de l'Etat de Californie, au Tribunal central du Comté d'Orange.

Lors de son étude sur le traitement des brûlures, dont ont bénéficié 20 millions de victimes de brûlures dans 73 pays, Docteur Xu, l'un des plus grands scientifiques du monde, a découvert en 1984 l'existence de la « cellule regénérative », que l'on a confirmé être, après 2000, une cellule souche positive pour la kératine-19 (Brevet américain 6991813B2). Il affirme que sa réputation auprès de la communauté scientifique a été diffamée par une déclaration publiée par les défendants, l'Assemblée des Nobel, lui causant des torts de par leur conduite. La plainte déclare que l'Assemblée des Nobel a réussi à susciter l'attention des médias par l'annonce de leurs Prix Nobel dans pratiquement toutes les organismes d'information et de publication du monde entier, ce qui prouve qu'ils peuvent affecter la perception d'un individu en colportant des informations erronées.

« Mon principal objectif, en déposant cette plainte, était de clarifier l'erreur de l'Académie suédoise et les déclarations mensongères pour la préservation de l'humanit&#
'/>"/>

SOURCE Mebo International
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Erste Klage gegen Nobelpreis-Organisation wegen Verleumdung und unlauterem Wettbewerb eingereicht
2. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
3. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
4. First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
5. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
6. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... (Nasdaq: FOLD ) today announced it plans to initiate ... drug in development for the treatment of Pompe Disease. ... pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. ... to Amicus, proposal for the Phase 1 study and subsequently ...
... PARIS, September 30 , ... to Achieve Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... ) announced today results of a,head-to-head study providing further evidence ... [rDNA] injection) compared,to twice-daily insulin detemir. The study was presented ...
... John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, ... Institute for Cancer Research (OICR) led a team of ... NEBNext(TM) DNA Sample Prep Reagents for use with OICR,s ... evaluation, "We are constantly striving for the best quality ...
Cached Biology Technology:Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... compound found in green tea shows great promise for ... tumors and a deadly congenital disease. The discovery ... Dr. Thomas Smith at The Donald Danforth Plant Science ... Philadelphia. Their findings are published in the recent article, ...
... A research team led by St. Jude Children,s ... for treatment of the childhood eye tumor retinoblastoma. Their ... cancer,s cellular origins are as scrambled as the developmental ... cancers that resemble a particular type of cell, researchers ...
... New research suggests that blood stem cells can be involved ... caused by the abnormal proliferation of mature cells. The study, ... the journal Cancer Cell , may guide future strategies ... CLL is a cancer of a type of mature ...
Cached Biology News:Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Stem cells central to pathogenesis of mature lymphoid tumors 2
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
...
Biology Products: